An evidence-based assessment of Pandia Health's safety record, regulatory standing, prescribing practices, and how it compares to alternatives for birth control and menopause telehealth.
An independent clinical review of Seed Health's DS-01 probiotic: safety record, regulatory status, strain-level evidence, third-party testing claims, and how it compares to alternatives.
An independent clinical assessment of who Strut Health is best suited for, covering men's hair loss, ED, GLP-1, and peptide prescriptions, with evidence-based analysis of costs, legitimacy, and alternatives.
An evidence-based review of Truepill's pharmacy infrastructure, regulatory compliance history, DEA and state board actions, and how it compares to alternative telehealth pharmacy platforms.
An evidence-based breakdown of who should consider Viome microbiome testing, what the science supports, where the evidence falls short, and how Viome compares to alternatives for gut health, metabolic optimization, and chronic disease management.
A clinical guide to Aetna (CVS Health) coverage for Vyleesi (bremelanotide), including prior authorization criteria, step therapy requirements, formulary tier, appeal strategies, and manufacturer savings options.
A clinician-level guide to the bremelanotide (Vyleesi) pre-surgery hold window, covering FDA labeling, cardiovascular pharmacology, anesthesia interactions, and practical perioperative management protocols.
A guide to bremelanotide (Vyleesi) safety during pregnancy and breastfeeding, covering mechanism of action, FDA labeling, reproductive toxicology data, and practical clinical guidance.
Vascepa isn't a statin swap for Lipitor. Added at 4g/day to statin therapy, it cut MACE by 25% in REDUCE-IT by targeting residual triglycerides.
A guide to switching anticoagulants safely, including warfarin-to-DOAC transitions, DOAC-to-DOAC switches, bridging protocols, INR timing, statin dose equivalence, and blood pressure medication titration during anticoagulation changes.
A fact-checked timeline of Khloé Kardashian's public weight-loss statements, the limits of appearance-based GLP-1 claims, and what semaglutide trials actually show.
A guide to tadalafil dosing, safety, and drug interactions in transplant recipients, people living with HIV, older adults, and other special populations. Includes trial data, FDA label guidance, and clinical decision frameworks.
A complete guide to UnitedHealthcare coverage for Cialis (tadalafil), including formulary tier, prior authorization criteria, step therapy requirements, appeal steps, and cash-pay alternatives.
A guide to tadalafil dosing for men aged 18-29, covering on-demand vs. Daily regimens, fertility considerations, safety data, and how to talk to your prescriber.
A guide to tadalafil safety in men aged 18 to 29, covering cardiovascular risks, fertility effects, drug interactions, daily vs. On-demand dosing, and when to see a doctor.
A clinician-focused guide to CJC-1295 (modified GRF) dosing adjustments in hepatic impairment, covering pharmacokinetics, GH axis physiology, safety monitoring, and evidence-based dose modification strategies.
A clinical-grade guide to aromatase inhibitor pharmacology, prescribing, billing codes, and prior-authorization strategies for anastrozole, letrozole, and exemestane. Written for prescribers and dispensing pharmacists.
A clinician-level review of DPP-4 inhibitor pharmacology, drug-drug interactions, dosing, and safety, with a full DDI table for sitagliptin, saxagliptin, alogliptin, and linagliptin.
A prescriber-level guide to choosing between sitagliptin, saxagliptin, alogliptin, linagliptin, and trelagliptin based on renal function, cardiac history, drug interactions, and cost.
A prescriber-level monograph covering the GHRH analog drug class: mechanism, pharmacokinetics, approved agents, clinical evidence, dosing protocols, safety, and monitoring for sermorelin, tesamorelin, and related compounds.
A prescriber-level guide to managing adverse events from GIP/GLP-1 dual agonists (tirzepatide), covering nausea, pancreatitis, gastroparesis, hypoglycemia, and injection-site reactions with dose titration protocols and monitoring schedules.
A prescriber-level guide to billing codes, prior authorization strategy, step therapy, and appeal tactics for tirzepatide and the GIP/GLP-1 dual agonist class. Includes real trial data, dose thresholds, and ICD-10 documentation requirements.
A clinician-level guide to tirzepatide titration schedules, dose-escalation pacing, GI tolerability management, and evidence-based tapering strategies for GIP/GLP-1 dual agonists.
A prescriber-level guide to GIP/GLP-1 dual agonists covering mechanism, agent selection, dosing, trial data, and clinical decision-making for weight loss, T2D, sleep apnea, and HFpEF.
A complete MD/PharmD-level guide to billing codes, prior authorization strategies, and prescribing essentials for GLP-1/GIP/glucagon triple agonists including retatrutide. Includes ICD-10, CPT, and appeal templates.
A prescriber-level monograph covering the pharmacology, clinical trial data, dosing considerations, and safety profile of GLP-1/GIP/glucagon triple agonists, with a focus on retatrutide and emerging agents in this drug class.
A prescriber- and pharmacist-level guide to GLP-1 receptor agonist drug classes, dosing, prior authorization strategy, step-therapy requirements, and appeals, with primary-source citations throughout.
A clinician-level guide to the GLP-1 receptor agonist drug class, including baseline workup, ongoing monitoring, dose titration, adverse-effect management, and cardiovascular outcome data.
A clinical-level guide to GLP-1 receptor agonist titration schedules, tapering protocols, dose adjustments for tolerability, and restart strategies, written for prescribers and dispensing pharmacists.
A clinician-level review of melanocortin receptor agonists, pharmacology, prototype bremelanotide (PT-141), dosing, safety, and special-populations guidance for prescribers and pharmacists.
A physician- and pharmacist-level review of NAD precursor drugs (NMN, NR, niacin), including evidence-based titration schedules, tapering protocols, dosing algorithms, and safety monitoring parameters.
A clinician-level guide to managing adverse events with PCSK9 inhibitors (evolocumab, alirocumab, inclisiran), covering injection-site reactions, musculoskeletal complaints, neurocognitive concerns, and step-by-step protocols for FH and post-ACS patients.
A complete prescriber-level guide to PCSK9 inhibitor drug classes, FDA-approved agents, clinical evidence, prescribing criteria, and step-by-step prior authorization strategies for evolocumab and alirocumab.
A complete drug-drug interaction table for PCSK9 inhibitors (evolocumab, alirocumab, inclisiran), plus class pharmacology, dosing, and prescribing guidance for FH and post-ACS patients.
A clinician-level guide to PCSK9 inhibitor drug class review, dosing titration, tapering strategies, and prescribing algorithms for FH and post-ACS patients, prepared by the HealthRX.com Editorial Team.
A clinician-level guide to recognizing, grading, and managing adverse events from PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) across ED, BPH, and pulmonary hypertension indications, with prescribing thresholds, drug interaction tables, and monitoring protocols.
A prescriber-level review of micronized progesterone versus synthetic progestins across special populations: pregnancy, menopause, cardiovascular risk, breast cancer history, liver disease, and more. Includes dosing, trial data, and guideline recommendations.
Dapagliflozin carries an amputation-risk signal seen with canagliflozin; learn screening steps, lower-limb monitoring, and when to hold SGLT2 therapy.
A complete MD/PharmD-level guide to SGLT2 inhibitor billing codes, prior-authorization requirements, step-therapy rules, and appeals strategy for empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin.
A prescriber-level summary of SGLT2 inhibitor use across special populations: heart failure, CKD, elderly patients, pregnancy, and more. Includes trial data, dosing guidance, and safety considerations.
A complete MD/PharmD-level guide to HMG-CoA reductase inhibitor pharmacology, prescribing tiers, prior-authorization strategy, and billing codes for statins used in ASCVD prevention.
A full clinical reference on HMG-CoA reductase inhibitors (statins): mechanism, dosing, ASCVD risk stratification, lab monitoring protocols, drug interactions, and adverse effect management. Written at MD/PharmD level.
A comparison of methylphenidate (Ritalin, Concerta) and amphetamine (Adderall, Vyvanse) covering mechanism, efficacy, side effects, abuse potential, and how to choose between them.
A clinical comparison of alendronate (Fosamax) and romosozumab (Evenity) for osteoporosis, including when to switch, which to use first, and what the evidence from FIT and ARCH actually shows.
A direct comparison of zoledronic acid (Reclast) and romosozumab (Evenity) covering efficacy, cost, insurance access, administration, and which patients benefit most from each drug.
A comparison of evolocumab (Repatha) and inclisiran (Leqvio), covering mechanism, LDL-C efficacy, MACE outcomes, dosing, and how to switch between them safely.
Yes, adding inclisiran can lower LDL-C by another 50 to 52% via a different pathway, often reaching goal when statin plus ezetimibe alone falls short.
A clinical comparison of modafinil (Provigil) and mixed amphetamine salts (Adderall XR) for cognitive performance, with an evidence-based review of the rationale and risks of combining both agents.
A clinical comparison of modafinil (Provigil) and lisdexamfetamine (Vyvanse) for cognition and mental performance, including the rationale and risks of combining both agents.
No head-to-head trial exists, but separate studies show similar ADHD-RS reductions (~18-19 points) for Vyvanse and Adderall XR, with differing onset and duration.
A clinical comparison of tirzepatide (Mounjaro) and liraglutide on weight loss, A1C reduction, dosing, and how to switch between them safely. prepared by the HealthRX.com Editorial Team.
A clinical comparison of semaglutide (Ozempic) and dulaglutide (Trulicity) covering efficacy, cardiovascular outcomes, dosing, side effects, and a step-by-step protocol for switching between them.
A detailed clinical and cost comparison of Ozempic (injectable semaglutide) vs Rybelsus (oral semaglutide) covering efficacy, pricing, insurance access, and who should use which.
A clinical comparison of semaglutide (Ozempic) vs liraglutide (Saxenda) for weight loss efficacy, dosing, side effects, and cost, with data from SUSTAIN-7, SCALE, and STEP trials.
Saxenda and liraglutide share the same molecule but differ sharply on approved dose, labeling, insurance coverage, and out-of-pocket cost. This clinical breakdown explains what patients and prescribers need to know before choosing between them.
A clinical comparison of Wegovy (semaglutide 2.4 mg) and Ozempic (semaglutide 0.5 to 2.0 mg) side-effect profiles, drawn from STEP-1, SUSTAIN-7, and FDA labeling, with practical guidance on switching and dose titration.
A clinical comparison of Wegovy (semaglutide 2.4 mg injection) and Rybelsus (oral semaglutide 3 to 14 mg) covering efficacy data, list prices, insurance coverage, and how to choose between them.
A detailed clinical comparison of Wegovy (semaglutide 2.4 mg) and Saxenda (liraglutide 3 mg) for weight loss, covering trial data, dosing, side effects, cost, and how to choose between them.
A clinical comparison of semaglutide 2.4 mg (Wegovy) and liraglutide 3 mg (Saxenda) side-effect profiles, drawn from STEP-1, SCALE, and post-market safety data. prepared by the HealthRX.com Editorial Team.
A detailed clinical comparison of Zepbound (tirzepatide) and liraglutide for weight loss, covering trial data from SURMOUNT-1 and SCALE Obesity, dosing, side effects, and how to choose between them.